You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice
|
|---|---|
| Published in |
Cardiovascular Diabetology, June 2015
|
| DOI | 10.1186/s12933-015-0243-y |
| Pubmed ID | |
| Authors |
Tao-Cheng Wu, Jenq-Shyong Chan, Chiu-Yang Lee, Hsin-Bang Leu, Po-Hsun Huang, Jia-Shiong Chen, Shing-Jong Lin, Jaw-Wen Chen |
| Abstract |
Factor Xa inhibitor is used for preventing venous thromboembolism (VTE) in adult patients receiving orthopedic operation. However, the role of factor Xa inhibitor, rivaroxaban, in angiogenesis is still unknown. Streptozotocin (STZ)-induced diabetic mice with model of hind-limb ischemia, were divided into non-diabetic control, diabetic control, and low- and high-dose rivaroxaban treatment groups, in order to evaluate the effect of rivaroxaban in angiogenesis. Doppler perfusion imaging showed that blood flow recovery was significantly increased, and more capillary density occurred in the rivaroxaban treatment group. In vitro studies, human endothelial progenitor cells (EPCs) treated with rivaroxaban had significant functional improvement in migration and senescence under hyperglycemic conditions. Rivaroxaban also increased endothelial nitric oxide synthase (eNOS) as well as vascular endothelial growth factor (VEGF) expressions in hyperglycemia-stimulated EPCs. Rivaroxaban promoted vessel formation in diabetic mice and improved endothelial progenitor cell function under hyperglycemic conditions. These effects may be associated with enhancement of expression of eNOS and VEGF. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Slovenia | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 21% |
| Student > Bachelor | 5 | 11% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Master | 5 | 11% |
| Student > Postgraduate | 3 | 6% |
| Other | 9 | 19% |
| Unknown | 10 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 38% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Agricultural and Biological Sciences | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Chemical Engineering | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 14 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2015.
All research outputs
#20,280,315
of 22,813,792 outputs
Outputs from Cardiovascular Diabetology
#1,214
of 1,379 outputs
Outputs of similar age
#199,503
of 239,955 outputs
Outputs of similar age from Cardiovascular Diabetology
#25
of 33 outputs
Altmetric has tracked 22,813,792 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,379 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,955 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.